NeuroSearch news from FierceBiotech
NewsALSO NOTED: ImClone hires Zuerblis for CFO post; Tekmira plans merger; Argos touts HIV data; and much more...
> ImClone Systems has hired Kenneth Zuerblis as its new chief financial officer. Zuerblis has been CFO at Enzon before his resignation in 2005 for personal reasons.
ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...
> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA.
NeuroSearch investors thrill to trial data
Shares of NeuroSearch surged on the news that its obesity drug tesofensine produced very good data in a Phase IIb trial. The drug hit all endpoints with a high statistical significance. One analyst... Read more...
| Press ReleasesPRESS RELEASE: NeuroSearch announces PhaseIIb obesity trial results NeuroSearch announces breakthrough tesofensine results from clinical Phase IIb study in obesity (“TIPO-1”) 17 September 2007 - Average weight loss of 12.6% and 11.2%, respectively, seen in the Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
